Status:
COMPLETED
Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
Lead Sponsor:
Biogen
Collaborating Sponsors:
Elan Pharmaceuticals
Conditions:
Crohn's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The primary objective of this study is to evaluate the long-term tolerability and safety of natalizumab when administered a dose of 300 mg intravenously (IV) to subjects with Crohn's Disease who have ...
Eligibility Criteria
Inclusion
- Male and Female Subjects 18 years and older with Crohn's Disease who have participated in studies CD251, CD301, CD303, CD306, or CD307 per protocol
Exclusion
Key Trial Info
Start Date :
July 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2004
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT00280956
Start Date
July 1 2002
End Date
September 1 2004
Last Update
June 16 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Performed only at CD251, CD301, CD303, CD306, and CD307 sites globally. No general public enrollment. The study is managed from the office of Elan Pharmaceuticals, Inc. in
San Diego, California, United States, 92121